FindTrial
Sign In

Crenezumab

DRUG7 trials

Sponsors

Genentech, Inc., Hoffmann-La Roche

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy Volunteer

Phase 1

A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose
CompletedNCT02427243
Genentech, Inc.Healthy Volunteer
Start: 2015-04-30End: 2015-07-31Updated: 2016-11-02

Phase 2

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
CompletedNCT01723826
Genentech, Inc.Alzheimer's Disease
Start: 2012-12-07End: 2017-02-08Updated: 2020-02-20
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
CompletedNCT01998841
Genentech, Inc.Alzheimer's Disease
Start: 2013-12-20End: 2023-08-08Updated: 2024-07-30
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
CompletedNCT03977584
Hoffmann-La RocheAlzheimer Disease
Start: 2019-06-10End: 2022-04-19Updated: 2024-03-15

Phase 3

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
TerminatedNCT02670083
Hoffmann-La RocheAlzheimer's Disease
Start: 2016-03-22End: 2019-05-31Updated: 2020-07-16
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
TerminatedNCT03114657
Hoffmann-La RocheAlzheimer's Disease
Start: 2017-03-29End: 2019-06-11Updated: 2020-07-16
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
TerminatedNCT03491150
Hoffmann-La RocheAlzheimer's Disease
Start: 2018-04-11End: 2019-05-31Updated: 2020-07-13

Related Papers

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.
2026-07-17
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1<sup>Glu280Ala</sup> mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.
2026-02-01
Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts.
2026-01-011 citations
Estimated age of amyloid plaque onset and impact of APOE4 in longitudinally assessed presenilin 1 E280A autosomal dominant Alzheimer’s disease mutation carriers
Alzheimer s & Dementia2025-12-01
The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.
2025-07-01
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
Alzheimer s & Dementia2023-12-011 citations
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials
Alzheimer s & Dementia2023-12-011 citations
Impact of reference region on longitudinal florbetapir PET SUVR changes from the API ADAD Colombia Trial
Alzheimer s & Dementia2023-12-01
18F GTP1 Tau PET image‐derived features improve the prediction of CDR‐SB progression in a multi‐modal model in prodromal to moderate AD
Alzheimer s & Dementia2023-12-01
Longitudinal lumbar puncture adherence in the Alzheimer’s Prevention Initiative Autosomal‐Dominant Alzheimer’s Disease Colombia Trial
Alzheimer s & Dementia2023-06-011 citations
Electrocardiogram differences in cognitively unimpaired PSEN1‐E280A carriers and non‐carriers from the Alzheimer’s Prevention Initiative Autosomal‐Dominant Alzheimer’s Disease Colombia Trial
Alzheimer s & Dementia2023-06-01
Feasibility of Neurofilament Light Chain as a Blood-Based Biomarker for Screening Across Neurological Diseases (P10-6.002)
Neurology2023-04-25
Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Trial
Alzheimer s & Dementia2022-12-01
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
JAMA Neurology2022-09-19195 citations
Evaluation of the Elecsys NeuroToolKit panel in early Alzheimer's disease populations across six clinical trials
Alzheimer s & Dementia2021-12-012 citations
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers.
2021-07-0420 citations
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease
Alzheimer s & Dementia2020-12-01
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
Journal of Alzheimer s Disease2020-06-1764 citations
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
Alzheimer s Research & Therapy2020-01-2243 citations
P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE
Alzheimer s & Dementia2019-07-012 citations

3 more papers not shown